company background image
MYOV

Myovant Sciences NYSE:MYOV Stock Report

Last Price

US$26.78

Market Cap

US$2.6b

7D

0%

1Y

40.4%

Updated

27 Nov, 2022

Data

Company Financials +
MYOV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MYOV Stock Overview

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.

Myovant Sciences Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Myovant Sciences
Historical stock prices
Current Share PriceUS$26.78
52 Week HighUS$26.90
52 Week LowUS$7.67
Beta2.24
1 Month Change0.22%
3 Month Change48.78%
1 Year Change40.36%
3 Year Change50.37%
5 Year Change103.26%
Change since IPO101.96%

Recent News & Updates

Not The Buyout Offer That Myovant Shareholders Hoped For

Oct 25

Recent updates

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28
Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14
Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13
Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12
Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23
Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Shareholder Returns

MYOVUS BiotechsUS Market
7D0%0.4%1.3%
1Y40.4%-14.4%-18.5%

Return vs Industry: MYOV exceeded the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: MYOV exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is MYOV's price volatile compared to industry and market?
MYOV volatility
MYOV Average Weekly Movement11.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MYOV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MYOV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016579Dave Marekhttps://myovant.com

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.

Myovant Sciences Ltd. Fundamentals Summary

How do Myovant Sciences's earnings and revenue compare to its market cap?
MYOV fundamental statistics
Market CapUS$2.59b
Earnings (TTM)-US$189.59m
Revenue (TTM)US$333.32m

7.8x

P/S Ratio

-13.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MYOV income statement (TTM)
RevenueUS$333.32m
Cost of RevenueUS$185.41m
Gross ProfitUS$147.91m
Other ExpensesUS$337.50m
Earnings-US$189.59m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.96
Gross Margin44.37%
Net Profit Margin-56.88%
Debt/Equity Ratio-69.9%

How did MYOV perform over the long term?

See historical performance and comparison